GlassScriptPhysician profile
Gary Joe Smith
NPI 1659375228
$8,213.01
in general payments reported to CMS, 2019-2025
50 companies · $939 in 2025
The $939 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $1,070 · 2021: $1,353 · 2022: $1,231 · 2023: $1,255 · 2024: $1,247 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,341 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,341.26 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,174.79 | 2019-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $1,092.42 | 2019-2025 | Skyrizi, Ubrelvy, Qulipta |
| Pfizer INC. | $929.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $753.53 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $657.42 | 2019-2025 | Taltz, Olumiant, Mounjaro |
| Amgen INC. | $548.40 | 2019-2025 | Enbrel, Tavneos, Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $296.80 | 2019-2022 | |
| Novo Nordisk INC | $229.45 | 2019-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $207.40 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $197.87 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $194.56 | 2023-2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $161.17 | 2022-2023 | Qelbree, Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.08 | 2019-2025 | Jardiance, Cyltezo |
| Astellas Pharma US INC | $141.32 | 2023-2024 | Myrbetriq, Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $107.68 | 2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.